What are the odds of serious harm from not doing allergy immunotherapy?
Evidence quality 3.88/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 2/5
- D2 Source authority
- 4/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 4/5
- D6 Prose
- 4/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 4/5
Lifetime probability · lifetime, US adult
1 in 11,111
0.009% lifetime chance
Most people overestimate this.
range 1 in 20,000 to 1 in 5,000
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Allergen immunotherapy — subcutaneous (SCIT, allergy shots) or sublingual (SLIT, drops or tablets) — is often presented to patients as essential to prevent allergic disease from worsening. The "allergic march" narrative holds that untreated allergic rhinitis progresses to asthma, and that immunotherapy can halt this trajectory. While there is evidence supporting immunotherapy's efficacy in symptom reduction and some evidence for prevention of new sensitizations in children, the framing that skipping immunotherapy leads to serious harm overstates the natural history. Most adults with allergic rhinitis manage effectively with antihistamines and nasal corticosteroids for decades without catastrophic progression. Fatal anaphylaxis from environmental allergens is exceedingly rare regardless of treatment status.
Rough estimate: Many allergists present immunotherapy as necessary to prevent progression; patients fear worsening without it
Source: editorial intuition, not polled
Actual
~1.5 fatal anaphylaxis events per million person-years (all causes); allergic rhinitis → asthma progression ~10-40% over decades
US general population, all-cause anaphylaxis fatalities
Show derivation
Fatal anaphylaxis from all causes occurs at approximately 0.5-1.0 per million person-years in the US (summing drug 0.27-0.51/M, food 0.03-0.3/M, venom ~0.1/M from PMC5589409). We use 1.5/M as a conservative upper bound. Over a 59-year adult lifetime at constant hazard: 1 − (1 − 0.0000015)^59 ≈ 0.000089, or roughly 1 in 11,000. This is an upper bound for the "serious harm from skipping immunotherapy" question, because: (a) most fatal anaphylaxis is from food, drugs, and venom — not the environmental allergens (dust mites, pollen, mold) that immunotherapy primarily targets; (b) immunotherapy itself carries a small but non-zero anaphylaxis risk (~1 death per million injection courses); (c) the more common concern — allergic rhinitis progressing to asthma — affects 10-40% of allergic rhinitis patients over decades, but asthma itself is manageable with modern inhaled corticosteroids and the attributable mortality from allergic asthma in treated populations is very low. The entry uses fatal anaphylaxis as the normalized metric because it is the most objectively severe outcome. The more common outcome of interest — progression from rhinitis to asthma — is not a disability in the traditional sense but a manageable chronic condition.
Caveats: This entry addresses environmental allergen immunotherapy (pollen, dust mites, m…
This entry addresses environmental allergen immunotherapy (pollen, dust mites, mold, pet dander) — not venom immunotherapy, which has a clearer risk-benefit case for patients with systemic venom reactions. The normalized metric uses fatal anaphylaxis as the severity anchor, but the more common concern is quality-of-life degradation from poorly controlled rhinitis and asthma progression. Immunotherapy is effective at reducing symptoms and may reduce the risk of developing asthma in children with rhinitis. The "overrated" framing applies to the fear of serious harm from NOT doing immunotherapy, not to immunotherapy's efficacy as a treatment. Patients with severe, medication-refractory allergic rhinitis or allergic asthma may benefit substantially from immunotherapy. The entry does not apply to food allergy oral immunotherapy (OIT), which has a different risk profile.
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Chiropractic neck manipulation
What are the odds of stroke or serious injury from chiropractic neck manipulation?
Hepatitis A (travel)
What are the odds of contracting hepatitis A as an unvaccinated traveler to an endemic region?
Infection from shared drink
What are the odds of catching a meaningful infection from sharing a drink bottle or cup?
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
The “allergic march” — the narrative that untreated allergic rhinitis inevitably progresses to asthma — contains a kernel of truth wrapped in considerable overstatement. Patients with allergic rhinitis do have a substantially increased risk of developing asthma — a retrospective cohort study found an odds ratio of 10.3 (univariate) and 7.8 (adjusted) compared with non-allergic individuals — and immunotherapy approximately halved the incidence of new-onset asthma (OR 0.53). But the baseline risk needs context: if 10-15% of rhinitis patients develop asthma over a decade without immunotherapy, and 5-8% develop it with immunotherapy, the absolute risk reduction is modest. More importantly, allergic asthma in the modern era is overwhelmingly manageable with inhaled corticosteroids, and the attributable mortality from well-treated allergic asthma is negligible.
The most severe theoretical outcome — fatal anaphylaxis — occurs at a rate of approximately 0.5-1.5 per million person-years across all causes, with drugs and food accounting for the vast majority of fatalities. Environmental allergens (pollen, dust mites, mold) are a negligible contributor to anaphylaxis deaths. This means the all-cause lifetime fatal anaphylaxis risk is roughly 1 in 11,000, and the share attributable to the allergens that immunotherapy targets is a small fraction of that. Immunotherapy itself carries a mortality risk of approximately 1 per 1.5 million injections — small in absolute terms, but not zero. For patients whose rhinitis is adequately controlled with antihistamines and nasal corticosteroids, the incremental benefit of immunotherapy in preventing serious harm (as opposed to improving quality of life) is marginal.
Where immunotherapy has its strongest evidence is in children, where it may genuinely interrupt the allergic march, and in venom allergy, where the risk-benefit calculus is clearer due to the real (if still small) risk of fatal Hymenoptera stings. For adults with environmental allergies managed on standard pharmacotherapy, the pressure to undergo 3-5 years of injection therapy is often framed in catastrophic terms — “your allergies will only get worse” — that the evidence does not fully support. Most adults with untreated allergic rhinitis live with the condition for decades without serious morbidity. The treatment decision is legitimately about symptom burden and quality of life, not about preventing an impending catastrophe.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] Current Allergy and Asthma Reports (PMC) — Fatal Anaphylaxis: Mortality Rate and Risk Factors
Fatal Anaphylaxis: Mortality Rate and Risk Factors- Statistic
Fatal anaphylaxis rates by cause: drug 0.27-0.51/M, food 0.03-0.3/M, venom ~0.1/M per year; aggregate ~0.5-1.0/M summing across causes- Excerpt
“"In the United States, using International Classification of Diseases-10 (ICD-10) categorization, the estimated fatal drug anaphylaxis rate increased significantly from 0.27 per million population in 1999-2001 to 0.51 per million population in 2008-2010." ”
- Source data from
- 2017-08-28
- Accessed
- 2026-04-18 · archived copy
- Calculation
- This review provides the mortality denominator for the most severe possible outcome of allergic disease. The 0.5-1.5 per million range covers all-cause anaphylaxis fatalities. Environmental allergens (pollen, dust mites) are a negligible share of fatal anaphylaxis triggers — the vast majority are drugs, food, and Hymenoptera venom. This means the risk of fatal anaphylaxis specifically attributable to the allergens that immunotherapy targets is well below the already-low all-cause rate.
-
[2] Respiratory Research (PMC) — Greater risk of incident asthma cases in adults with Allergic Rhinitis and Effect of Allergen Immunotherapy: A Retrospective Cohort Study
Greater risk of incident asthma cases in adults with Allergic Rhinitis and Effect of Allergen Immunotherapy: A Retrospective Cohort Study- Statistic
Allergic rhinitis patients had 7.8-10.3x greater risk of developing asthma; immunotherapy reduced new-onset asthma (OR 0.53)- Excerpt
“"Treatment with allergen immunotherapy was significantly and inversely related to the development of new onset asthma (OR, 0.53; 95%CI, 0.32-0.86). Presence of allergic rhinitis at the start of the study was highly predictive of development of new onset asthma after 10 years (OR, 10.3; 95%CI, 4.8-21.8)." ”
- Source data from
- 2006-01-06
- Accessed
- 2026-04-18 · archived copy
- Calculation
- This retrospective cohort study provides the key evidence for the "allergic march" — rhinitis patients have ~8-10x the odds of developing asthma compared to non-allergic controls (OR 10.3 univariate, 7.81 multivariate). Immunotherapy approximately halved the risk of new-onset asthma (OR 0.53). However, this is a relative risk reduction: if the baseline risk of developing asthma over 10 years is 10-15% for rhinitis patients, immunotherapy reduces it to ~5-8%. Important context: developing asthma is not the same as developing serious harm — most allergic asthma is well-controlled with inhaled corticosteroids.
-
[3] StatPearls (NCBI Bookshelf) — Allergy Immunotherapy
Allergy Immunotherapy- Statistic
SCIT efficacy 80-90% for venom, 70-80% for environmental allergens; fatal reactions ~1 per million injection courses- Excerpt
“"Allergen immunotherapy is the only modality that can modify the immune response upon exposure to aeroallergens and venom allergens. From 1985 to 1993, 52.3 million immunotherapy administrations resulted in 35 deaths." ”
- Source data from
- 2024-05-01
- Accessed
- 2026-04-18 · archived copy
- Calculation
- StatPearls provides the treatment efficacy and risk data. The 35 deaths per 52.3 million administrations yields roughly 1 death per 1.5 million injections. This is important for the risk-benefit framing: immunotherapy itself carries a small but real mortality risk. If the condition being treated (environmental allergies) has a near-zero mortality risk when managed with antihistamines, the risk-benefit calculus for immunotherapy depends primarily on quality-of-life improvement rather than mortality prevention.